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ABSTRACT
Objective There is growing evidence from observational 
studies that lifestyle factors such as obesity, an unhealthy 
diet and lack of physical activity are associated with poor 
long- term outcome in women with breast cancer. The 
primary objective of the lifestyle modification part of the 
Simultaneous Study of Docetaxel Based Anthracycline 
Free Adjuvant Treatment Evaluation, as well as Life Style 
Intervention Strategies (SUCCESS C) Trial is to investigate 
the effect of an individualised lifestyle intervention 
programme aiming at moderate weight loss on disease- 
free survival in women with HER2/neu- negative breast 
cancer. Secondary objectives include the effect of the 
intervention on body weight, cardiovascular risk and 
quality of life.
Methods The SUCCESS C Trial is an open- label, 
multicentre, randomised controlled phase III study using 
a 2×2 factorial design in women with newly diagnosed 
HER2/neu- negative intermediate- risk to high- risk breast 
cancer. The first randomisation served to compare 
disease- free survival in patients treated with two different 
chemotherapy regimens (3642 participants). The second 
randomisation served to compare disease- free survival 
in patients with a body mass index of 24–40 kg/m² 
(2292 participants) receiving either a telephone- based 
individualised lifestyle intervention programme for 
moderate weight loss or general recommendations for 
a healthy lifestyle for 2 years. Outcome analyses will be 
conducted after 5 years of follow- up.
Perspective This study will provide information on 
the efficacy and safety of a comprehensive lifestyle 
intervention programme on disease- free survival in a large 
cohort of women with breast cancer. EU Clinical Trials 
Identifier: 2008-005453-38.
INTRODUCTION
There is growing evidence from a variety of 
observational studies that lifestyle factors 
contribute substantially to the risk of devel-
oping breast cancer. These factors include an 
unhealthy diet and a lack of physical activity, 
and overweight/obesity.1–3
While the database for primary prevention 
of breast cancer is considerable, there is much 
less information on the role of lifestyle factors 
for the prognosis of women with diagnosed 
breast cancer. The evidence for similar asso-
ciations between lifestyle factors mentioned 
and mortality from breast cancer is limited, 
as the risk of relevant confounding is substan-
tial in many studies.4 However, the conclusion 
of many systematic reviews and meta- analyses 
was that greater body fatness, measured by 
weight and body mass index (BMI), is signifi-
cantly associated with increased mortality.5–7
Although observational studies have 
linked obesity and poor lifestyle to a poorer 
outcome of breast cancer, there is an urgent 
need to perform randomised controlled 
trials, as it is not fully clear if the reported 
associations are causal and to what extent life-
style changes may affect cancer prognosis. To 
date, most lifestyle intervention studies are 
small and have mainly evaluated their effect 
on quality of life or intermediate end points 
such as biomarkers linked to breast cancer.8 
What this paper adds
 ► There is limited evidence that lifestyle is relevant for 
the prognosis of breast cancer.
 ► Weight loss in women with breast cancer improves 
potential biomarkers of disease progression.
 ► Randomised controlled intervention trials are urgent-
ly needed to explore the potential of comprehensive 
lifestyle modification on breast cancer survival.
 ► This paper describes the lifestyle intervention pro-
gramme of the SUCCESS- C trial.
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There is also only a small number of clinical studies on 
the effect of weight loss in women with breast cancer.9 10 
Two large- scale intervention studies initiated in the 90s 
have examined the effect of reduction in fat intake on 
breast cancer recurrence and mortality. In the Women’s 
Intervention Nutrition (WIN) Study women with breast 
cancer received an intervention focussing on the reduc-
tion of fat intake. After a follow- up of 5 years a reduc-
tion of relapse events was observed compared with the 
control group (HR of 0.76 (p=0.034 for adjusted Cox 
model analysis)).11 In contrast, the Women’s Healthy 
Eating and Living (WHEL) Trial observed no effect of a 
diet low in fat and high in vegetables, fruit and fibre on 
breast cancer recurrence or mortality.12 A potential expla-
nation for these discrepant findings may be that WIN—in 
contrast to WHEL—observed a modest weight loss, which 
might have influenced the outcome. Both studies did 
not consider other lifestyle components such as physical 
activity and management of obesity.
Therefore, the aim of this study was to investigate 
the effect of a comprehensive lifestyle intervention 
programme including a healthy, moderately hypocaloric 
diet and an increase in physical activity on the prognosis 
of breast cancer in women at intermediate risk to high 
risk. This article describes the design and procedures of 
the lifestyle modification part of the study in detail.
METHODS
Study design
The SUCCESS C Study (acronym for ‘Simultaneous 
Study of Docetaxel Based Anthracycline Free Adjuvant 
Treatment Evaluation, as well as Life Style Intervention 
Strategies’) is an open- label, multicentre, randomised, 
controlled phase III study in women with newly diag-
nosed HER2/neu- negative breast cancer. There were two 
randomisations after recruitment: a first randomisation 
for chemotherapy and a second randomisation for the 
lifestyle intervention part, confined to women with a BMI 
between 24 kg/m2 and 40 kg/m², thereby representing a 
2×2 factorial design. A first description of the SUCCESS 
C Study detailing chemotherapy and endocrine treat-
ment was published previously.13 Randomisation was 
performed after surgical treatment when the inclusion 
criteria were met and the written informed consent form 
was signed by the patient.
Primary objectives
The primary objectives of the SUCCESS C Trial were:
 ► To compare disease- free survival in patients treated 
with a combination of 5- Fluorouracil/epirubicin/
cyclophosphamide followed by docetaxel or 
docetaxel/cyclophosphamide continuously.
 ► To compare disease- free survival after randomisation 
of patients into a comprehensive and individualised 
lifestyle intervention programme (aiming at moderate 
weight loss) or general lifestyle recommendations.
Disease- free survival was defined as the time from 
randomisation to the diagnosis of locoregional recur-
rence, distant metastases or death. Locoregional recur-
rence was defined as any relapse in the area of primary 
surgery and/or ipsilateral regional axillary lymph nodes 
including the nodules of the infraclavicular or supraclav-
icular fossa. Any other tumour manifestation was defined 
as distant disease. As cardiometabolic disease is the major 
cause of death in women of this age and as women with 
breast cancer may also benefit from an improvement in 
cardiovascular risk factors, we were also interested to study 
changes in cardiovascular risk, in addition to changes in 
body weight.
Secondary objectives
 ► Changes in body weight and waist circumference.
 ► Changes in blood pressure and cardiometabolic risk 
factors (blood glucose, HbA1c, total, low density 
lipoprotein- cholesterol and high density lipoprotein- 
cholesterol, triglycerides).
 ► Clinical manifestation of type 2 diabetes, hyperten-
sion and cardiovascular disease.
 ► Changes in dietary habits and patterns and in physical 
activity.
 ► Change in health- related quality of life.
 ► Change in Eastern Cooperative Oncology Group 
performance status.
 ► Change in biomarkers (eg, adiponectin, insulin).
Study population
Participant enrolment
In total, 3642 participants have been enrolled between 
February 2009 and August 2011. Finally, 231 recruiting 
study centres throughout Germany were contributing 
to the study. Two thousand two hundred and ninety- two 
participants with a BMI of 24–40 kg/m² (63% of total 
participants) were randomised for the lifestyle interven-
tion part of the study.
Patients were recruited into the study not later than 6 




Eligible patients had to meet the following criteria:
 ► Women ≥18 years of age.
 ► Primary epithelial invasive carcinoma of the breast 
pT1–4, pN0–3, pM0.
 ► No evidence of HER2- neu overexpressing (IHC neg 
or +) or amplifying (FISH−) tumour.
 ► Histopathological proof of axillary lymph node metas-
tases (pN1−3) or high- risk node negative, defined as at 
least two criteria of the following: pT ≥2, histopatho-
logical grade 3, age ≤35, negative hormone receptor.
 ► Complete resection of the primary tumour with 
margins of resection free of invasive carcinoma not 
more than 6 weeks ago.
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 ► Willingness to participate in a telephone- based life-
style intervention programme.
 ► Ability to understand the nature of the study and to 
give written informed consent.
Exclusion criteria
Patients were excluded from the study for any of the 
following reasons:
 ► Inflammatory breast cancer.
 ► Cardiomyopathy with impaired ventricular function 
(New York Heart Association (NYHA) >II), cardiac 
arrhythmias influencing left ventricular ejection frac-
tion and requiring medication, history of myocardial 
infarction or angina pectoris within the last 6 months, 
or arterial hypertension not being controlled by 
medication.
 ► Patients in pregnancy or lactation (in premenopausal 
women, anticonception had to be assured).
 ► Insulin- requiring diabetes mellitus (non- insulin- 
requiring patients with type 2 diabetes were eligible 
for the study).
 ► Serious digestive and/or absorptive problems that 
exclude adherence to the dietary recommendations 
of the study.
 ► Self- reported inability to walk at least 1 km (at any 
pace).
 ► Cardiovascular, respiratory or musculoskeletal disease 
or joint problems that precluded moderate physical 
activity.
 ► Psychiatric disorders or conditions that would 
preclude active participation.
 ► Patients not sufficiently fluent in German language to 
understand the nature of this study.
Randomisation
Both first (chemotherapy treatment) and second (life-
style intervention) randomisation took place at the time 
between resection of the primary tumour and the start 
of chemotherapy. All enrolled patients with a BMI of 
24–40 kg/m² were randomised for the lifestyle interven-
tion. Randomisation was balanced between the two study 
arms (1:1) and performed using a block size of 4. While 
the first randomisation for chemotherapy treatment was 
stratified for axillary lymph node involvement, hormone 
receptor status, histopathological grading, menopausal 
status and patient BMI, no stratification was imple-
mented with regard to the second randomisation to indi-
vidualised lifestyle intervention versus general lifestyle 
recommendations.
The lifestyle intervention programme
The lifestyle intervention programme of the SUCCESS C 
Trial was based on the Diabetes Prevention Programme 
(DPP).14 The detailed intervention manual of DPP is avail-
able online (http://www. bsc. gwu. edu/ dpp/ manuals. 
html. doc).
For the purpose of this study, the DPP was modified 
according to new developments in weight management 
and the specific requirements of the study. New elements 
included principles to lower energy density to better 
maintain satiety,15 a greater focus on reducing sugar- 
sweetened beverages and a more individualised approach 
with greater flexibility to consider individual preferences. 
Furthermore, the intervention was culturally adapted to 
the lifestyle and eating habits in Germany as well as to 
the special situation of women with breast cancer. Nutri-
tion recommendations were adapted according to the 
World Cancer Research Fund (WCRF),1 for example, for 
limitation on or renouncing alcohol consumption, for fat 
reduction, for limitation of red meat and processed meat, 
for sufficient intake of protein, for enhancing intake of 
fibre, fruit and vegetables. High- caloric soft drinks—also 
fruit juice—should be avoided, preferring low- caloric 
or calorie- free beverages. Physical activity recommenda-
tion was adapted to the individual situation. The team 
of coaches was additionally supervised by a psycho- 
oncologist to be aware of the psychological situation and 
problems of patients with breast cancer.
For applicability reasons, the programme was trans-
formed into a semistructured telephone- based interven-
tion mode supplemented with detailed information and 
training material and newsletters sent by mail. As partic-
ipants were living disseminated over the country and 
were recruited through a 3- year period, the telephone- 
based intervention was considered as an adequate way to 
provide the lifestyle programme in a highly standardised 
manner. The 2- year lifestyle intervention programme was 
planned to start 3 months or 6 months after the end of 
chemotherapy to allow physical recovery.
Goals of the intervention
The weight loss goal of the intervention should be 
achieved after 6 months, defined as a moderate reduction 
of body weight by 5% (not more than 10 %) at a baseline 
BMI of 24–29.9 kg/m² and by 10% (not more than 20%) 
at a baseline BMI of 30–40 kg/m² with subsequent weight 
maintenance. Participants should not fall below a BMI of 
22 kg/m².
Key components of the intervention
The intervention programme comprised the following 
components:
1. A moderate caloric restriction with an estimated ener-
gy deficit of 500 kcal per day. The level of recommend-
ed caloric intake was between 1200 kcal and 1800 kcal 
per day based on the calculation of energy expendi-
ture, using a formula developed for the adult German 
population.16
2. The diet included a fat reduction to 20%–25% of the 
total energy intake. At the same time, the intake of 
wholegrain products, fruit and vegetables should be 
increased. Targets for fruit intake were two to three 
portions at 150 g/day. Targets for vegetables were two 
to three portions at 200–300 g/day. Other targets for 
dietary intake were two to three portions of dairy prod-
ucts per day, two to three portions (100–150 g) of fish 
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per week, two to three portions (100–150 g) of meat 
per week, very small amounts of processed meat (max-
imum 20–30 g/day). Rapeseed and olive oil as well as 
diet margarine should be preferred. Women were en-
couraged to limit alcohol consumption to a maximum 
10 g per day for 3 days a week if acceptable.
3. An increase in physical activity was intended tailored 
to the individual fitness with brisk walking as the main 
recommendation. Participants were advised to practise 
regular physical activity of moderate intensity, at least 
150 min per week.
4. Regular self- monitoring and recording of body 
weight—at least once a week—was advised.
5. Additionally the intervention included behavioural 
components based on cognitive social therapy,17 such 
as maintaining motivation, overcoming obstacles to 
success, relapse prevention, emotional distress man-
agement with preprints for documentation of the 
participants.
Following the DPP, women assigned to the lifestyle 
intervention part received 19 telephone calls from their 
lifestyle coaches during the 2 years. Up to three addi-
tional calls were offered by the coaches in case of a need 
to reinforce aspects of the intervention or dealing with 
barriers to success. The 19 telephone calls with a mean 
duration of 30 min were scheduled as follows:
(1) Intensive phase (month 1): weekly for weeks 0, 1, 2, 
3, 4; (2) Consolidation phase (month 2–6): every 2 weeks 
for months 2 and 3, monthly for months 4–6; (3) Mainte-
nance phase (months 7–24): every 2 months for months 
7–12, every 3 months for months 13–24. Consequently, 
during the first 6 months there were at least 12–13 calls 
plus a welcome call and up to 3 calls optionally. The 
telephone calls were standardised and semistructured 
according to DPP (concerning topics and intervals) and 
conducted by specifically trained lifestyle coaches from 
almeda GmbH, a medical service centre in Munich which 
is specialised in the delivery of telephone- based disease 
management and lifestyle modification programmes. 
The lifestyle coaches had primary qualification such as 
dieticians, ergotherapists or nurses and were receiving 
continuous training in communication techniques. Five 
per cent of the telephone calls were supervised. Every 
effort was made to keep the same lifestyle coach for 
individual participants throughout the study. In case of 
severe psychological problems of participants, a psycho- 
oncologist was available for immediate intervention.
Support material for the participants of the intervention group
Based on the DPP manual, the support material for the 
intervention group contained
 ► A detailed manual with 16 different chapters referring 
to the corresponding telephone calls containing key 
messages.
 ► A fat counter in the form of a booklet informing about 
the fat content of foods/meals.
 ► A workbook with instructions and self- monitoring 
tools (eg, eating habits, physical activity).
 ► A newsletter sent at 6 months and 18 months.
 ► For the solution of obstacles confronting individual 
participants, the coaches also had access to a toolbox 
including for example, gymnastic articles, cookbooks 
or other gifts.
Initiation and implementation of the intervention
After confirmation by the study doctor a ‘starter- package’ 
was handed over to the women. The main constituents 
of the ‘starter- package’ were a preprint of a 7- day dietary 
record including a physical activity record as well as a 
pedometer. Patients were encouraged to record their 
dietary intake and physical activity. This baseline infor-
mation was used to tailor the lifestyle programme to the 
individual wishes and needs of the patient.
Control group
The patients of the control group received a standardised 
mail- based low- level intervention focussing on healthy 
living. This programme included mailings at study entry 
and 12 months later with general information on a 
healthy lifestyle. Additionally, the participants allocated 
to the control group received a 1 year free subscription to 
‘Vital’, a monthly German health magazine.
Data collection
Baseline and follow-up assessment for the lifestyle intervention 
study
A physical examination at baseline was performed in the 
local study centre as well as during all follow- up examina-
tions at months 6, 12, 24 and after 48 months. Women of 
the intervention group and control group underwent the 
following measurements at the local study centre:
Height to the nearest 0.5 cm, weight to the nearest 
100 g (in indoor clothing without shoes), waist circumfer-
ence using a flexible tape midway between the lower rib 
margin and the iliac crest with the patient in a standing 
position and normal breathing, blood pressure at rest and 
fasting blood sampling. Dietary intake was assessed using 
7- day dietary records. Physical activity was assessed using 
the International Physical Activity Questionnaire (Inter-
national Physical Activity Questionnaire (IPAQ), German 
version).18 Health- related quality of life was measured 
using the following questionnaires: The Hospital Anxiety 
and Depression Score (HADS) Questionnaire (‘Hospital 
Anxiety and Depression Scale’),19 the European Asso-
ciation for Research and Treatment of Cancer Quality 
of Life Questionnaire (EORTC QLQ)- C30, combined 
with the special module for breast cancer EORTC QLQ- 
BR23,20 and the ‘Belastungsthermometer’ Question-
naire.21 All questionnaires were sent out 4 weeks prior to 
the follow- up examinations.
Blood collection
During the regular visits in the local study centres, fasting 
blood samples were collected and handled according to 
predefined standard operation procedures (SOPs) for 
the measurement of routine and safety parameters. In 
addition, serum and plasma biosamples were stored in 
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the study centres at –20°C, then rapidly transferred to the 
central biobank and kept at –80°C.
Safety, documentation and data management
All adverse events were documented by the study centres 
and reported to the study coordinator board. The inde-
pendent Data Monitoring and Safety Board was regu-
larly informed about any safety issues. All data on patient 
recruitment and treatment, anthropometric and labora-
tory variables, blood pressure as well as on medication 
and concomitant diseases were documented in a central 
databank.
Discontinuation of the lifestyle intervention
The weight management programme was stopped in the 
following situations:
 ► Any medical circumstance considered reasonable by 
the treating study doctor or another primary physi-
cian (eg, new onset of congestive heart failure).
 ► Disease recurrence: women who experienced ipsi-
lateral or locoregional breast cancer events or new 
contralateral breast cancer primaries or distant meta-
tastasis have met the primary study outcome and were 
withdrawn from the study (for safety reasons).
 ► Development of a non- breast primary invasive tumour 
was handled in a manner similar to disease recurrence.
 ► Request by the patient.
Feasibility evaluation
Before starting the intervention, a pilot run involving 20 
female staff members—with no history of breast cancer—
was conducted to get feedback on the lifestyle modifica-
tion programme for clarity, comprehension and ease of 
use. Comments were discussed and minor changes were 
made to improve the programme, mainly with regard to 
understandability and feasibility (data not shown).
Statistical analysis
According to the sample size calculation based on the 
chemotherapy intervention, SUCCESS C was planned to 
recruit 3546 participants with an accrual time of 3 years 
and a follow- up period of 5 years from the end of acrual. 
It was expected that 62% of all participants entering the 
trial have a baseline BMI ≥24 kg/m², resulting in 2198 
patients entering the lifestyle intervention. With this 
sample size there is a power of 80% to detect a difference 
of 6% in disease- free survival rates at 5 years.
The 5- year disease- free survival rate will be compared 
between the two lifestyle intervention arms using the χ2 
test. Median disease- free survival will be assessed using the 
Kaplan- Meier method and compared using the log- rank 
test. Multivariable Cox regression models adjusted for 
other factors known to affect survival will be used to test 
whether there is an independent effect of lifestyle inter-
vention on survival. Secondary outcomes will be evaluated 
with mixed models for repeated measurements adjusting 
for baseline weight, chemotherapy and BMI. All analyses 
will be performed using the statistical programme SPSS, 
V24.0 (IBM Corp, Armonk, New York, USA).
DISCUSSION
Despite growing evidence from observational studies that 
lifestyle factors such as elevated body weight, lack of phys-
ical activity and a poor diet negatively influence the prog-
nosis of women with breast cancer,4 6 22 there are little data 
available as to whether lifestyle intervention programmes 
can affect survival in patients with breast cancer. To date, 
only two large- scale randomised controlled interven-
tion studies have tried to examine the effect of lifestyle 
intervention on breast cancer prognosis with conflicting 
results.11 12 A general disadvantage of both studies was 
that the intervention programmes were not comprehen-
sive and did not include important lifestyle components, 
for example, increase in physical activity.
Previous observational studies and meta- analyses 
have provided limited evidence for a positive influence 
of weight reduction on prognosis,1 5 but this is not yet 
proven by an intervention trial. Therefore, the lifestyle 
intervention part of the SUCCESS C Study was designed 
to focus on weight loss in newly diagnosed women with 
intermediate- risk to high- risk breast cancer. The avail-
able data justify the inclusion of premenopausal as well 
as postmenopausal women,5 23 regardless of the receptor 
status.24
The central components of the intervention programme 
included a moderate energy restriction, a healthy diet 
and an increase in moderate physical activity to at least 
150 min per week to achieve a moderate weight loss of 
5%–10%.3 4 Waist circumference was measured as an indi-
cator of the fat distribution pattern which is considered 
as risk factor for breast cancer.1 A limitation of the study 
is that we did not assess body composition by established 
methods.
To minimise the frequently observed weight regain 
the lifestyle intervention programme comprised regular 
self- monitoring of weight, diet, physical activity and 
behaviour as well as a special focus on behavioural 
aspects, for example, motivation training, overcoming 
obstacles, relapse prevention. Recording of diet and phys-
ical activity for self- monitoring was recommended daily 
during the first 6 months and later on optionally.
In recent years, a number of weight loss intervention 
studies with mostly small sample sizes and short duration 
of follow- up have been performed in women with breast 
cancer.9 10 Most of these studies evaluated changes in 
body weight and quality of life or biomarkers linked to 
cancer risk, but not hard end points such as disease- free 
survival.8 25 26
Recently, the results of two larger weight loss trials with 
longer intervention periods were published. In the life-
style intervention in adjuvant treatment of early breast 
cancer study (LISA) Trial, using a similar protocol as the 
SUCCESS C Study, 338 women with early breast cancer 
were included and underwent a 2- year telephone- based 
weight loss and maintenance programme. Mean weight 
loss after 24 months was 3.1% vs 0.4% in the control 
group.27 In the Exercise and Nutrition Enhance Recovery 
and Good health for You (ENERGY) Trial, a behavioural 
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weight loss intervention in 692 overweight or obese breast 
cancer survivors resulted in a mean weight reduction of 
3.7% in the intervention group compared with 1.3% in 
the control group.28
In the SUCCESS C Study, the lifestyle intervention 
programme was provided as a semistructured telephone- 
based intervention supplemented with detailed materials 
and newsletters sent by mail, as this was considered to be 
the most appropriate way to perform the lifestyle interven-
tion in participants living disseminated over the country 
and recruited during a 3- year period. The feasibility of 
telephone- based and mail- based approaches to modify 
lifestyle in women with breast cancer has already been 
demonstrated in other lifestyle intervention studies.12 27–29
There is broad agreement that randomised controlled 
trials with large sample sizes are needed to study 
the effects of comprehensive lifestyle intervention 
programmes on cancer prognosis in breast cancer survi-
vors. The SUCCESS C Study is one of only a few such 
studies. Another ongoing large- scale lifestyle interven-
tion study is the Diana-5 (Diet and Androgens) Trial 
which is examining the effectiveness of a Mediterranean- 
macrobiotic diet in women with early stage invasive 
breast cancer.30 Finally, the Alliance A011401 project 
tries to evaluate the effect of weight loss in the adjuvant 
treatment of overweight and obese women with breast 
cancer.31
It is expected that the lifestyle intervention may show 
beneficial effects on other diseases beyond the hypoth-
esised effect on breast cancer survival. Thus, as breast 
cancer is becoming a chronic disease,32 and patients are 
at risk of developing a variety of other lifestyle- associated 
diseases including type 2 diabetes or cardiovascular 
disease, their prognosis may be strongly influenced 
by such diseases.33 It is also noteworthy that metabolic 
disturbances may act as a common soil for both breast 
cancer and cardiovascular disease.34 Therefore, adopting 
a healthy lifestyle may confer additional benefit for health 
and life expectancy in women with breast cancer.
CONCLUSION
The lifestyle intervention part of the SUCCESS C Study 
addresses the important, but still unanswered question if 
a long- term modification of lifestyle in women with breast 
cancer may have a positive impact on disease- free survival. 
The study will also provide robust data on the efficacy and 
safety of a weight loss and comprehensive lifestyle modifi-
cation programme in these patients.
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